BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2023 6:05:28 AM | Browse: 147 | Download: 401
 |
Received |
|
2023-01-26 12:20 |
|
Peer-Review Started |
|
2023-01-26 12:24 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-04-11 16:52 |
|
Revised |
|
2023-04-14 08:12 |
|
Second Decision |
|
2023-05-04 03:13 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-05-05 15:34 |
|
Articles in Press |
|
2023-05-05 15:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-06-08 08:43 |
|
Publish the Manuscript Online |
|
2023-06-15 06:05 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana, Tawithep Leowattana and Pathompthep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, BMed, MD, MSc, PhD, Full Professor, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Rachatawee 10400, Bangkok, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Biliary tract cancers; Gemcitabine and cisplatin combination; Fibroblast growth factor receptor 2 inhibitors; Isocitrate dehydrogenase 1 inhibitors; Neurotrophic tyrosine receptor kinase gene fusion inhibitors; Immune checkpoint inhibitors; Microsatellite instability high; Infrigatinib; Pemigatinib |
| Core Tip |
There have been several developments in the field of advanced biliary tract cancer (BTC) therapy in recent years. First, the care of these hepatobiliary malignancies has improved as a result of better knowledge of the molecular basis of BTC. The Food and Drug Administration's approval of pemigatinib, infigratinib, and ivosidenib for fibroblast growth factor receptor 2-rearranged and isocitrate dehydrogenase 1-mutant cholangiocarcinoma illustrates the paradigm shift that the arrival of targeted agents has really brought about. Second, patients receiving modified fluorouracil, oxaliplatin, and liposomal irinotecan with fluorouracil-leucovorin, respectively, as second-line treatments after progressing to first-line cisplatin-gemcitabine, showed an overall survival advantage in the newly released Advanced Biliary Tract Cancer-06 and NIFTY studies. |
| Publish Date |
2023-06-15 06:05 |
| Citation |
Leowattana W, Leowattana T, Leowattana P. Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer. World J Gastrointest Oncol 2023; 15(6): 959-972 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i6/959.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i6.959 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
